Effect of once daily and twice daily sustained release theophylline formulations on daytime variation of bronchial hyperresponsiveness in asthmatic patients

Marcello Ferrari, Mario Olivieri, Guido Lampronti, Lucio Bonazza, Cristina Biasin, Pantaleo Nacci, Giorgio Talamini, Vincenzo Lo Cascio

Abstract

Background – Previous studies evaluating spirometric values and symptoms have shown that once daily theophylline administered in the evening produces greater stabilisation of the airway function in asthmatic patients than the prototype theophylline given twice a day. The aim of this study was to compare the effects on bronchial responsiveness to methacholine of an ultrasustained release theophylline formulation (Diffumal-24, Malesci, Florence, Italy) administered once a day, a sustained release theophylline formulation (Theo-Dur, Recordati, Milan, Italy) administered twice a day, and placebo.

Methods – The study was performed in 12 adult patients with asthma using a randomised, double blind, three phase, crossover design. Each phase lasted seven days and was followed or preceded by at least three days of theophylline washout. Diffumal-24 was administered once a day at 20.00 hours whereas Theo-Dur was given twice a day at 08.00 hours and 20.00 hours. In each patient the total daily dose of theophylline was the same during both phases. The dose of the two active preparations was titrated to individual needs before the beginning of the study and then given in divided or once daily doses. At 08.00, 14.00, and 20.00 hours on day 7 of each phase assays, and the development of sustained release formulations have led to a safer and more effective use of the drug. The therapeutic advantages of sustained release formulations have mainly been attributed to their ability to reduce fluctuations in plasma theophylline concentrations and, consequently, to keep serum levels of the xanthine within the narrow therapeutic range during the 24 hours. For this reason, slow release theophylline formulations given twice a day are theoretically more effective than the more recently introduced ultrasonad release theophylline formulations designed to allow once a day dosing which produce larger fluctuations in serum levels of the xanthine.

Oral theophylline formulations are widely used in the treatment of bronchial asthma. During the past 10 years increased knowledge of the pharmacokinetics, availability of theophylline assays, and the development of sustained release formulations have led to a safer and more effective use of the drug. The therapeutic advantages of sustained release formulations have mainly been attributed to their ability to reduce fluctuations in plasma theophylline concentrations and, consequently, to keep serum levels of the xanthine within the narrow therapeutic range during the 24 hours. For this reason, slow release theophylline formulations given twice a day are theoretically more effective than the more recently introduced ultrasonad release theophylline formulations designed to allow once a day dosing which produce larger fluctuations in serum levels of the xanthine.

Conclusions – In adults with stable bronchial asthma treatment with a single dose of Diffumal-24 administered in the evening improved airflow obstruction and reduced bronchial hyperresponsiveness.

Keywords: theophylline, bronchial hyperresponsiveness, bronchial asthma.
Previous studies evaluating spirometric values and symptoms have shown that once a day theophylline administered in the evening produced greater stabilisation of airway function than the prototype theophylline formulation given twice a day to asthmatic patients. In recent years emphasis on bronchial hyperresponsiveness as an important feature of asthma has become generally accepted. We have therefore compared the effects on bronchial hyperresponsiveness in adult patients with asthma of once a day theophylline administered in the evening with that of a reference theophylline formulation given twice a day.

Methods

SUBJECTS

Twelve non-smoking asthmatic subjects (eight men) of mean age 41.5 years (range 23–62) took part in the study (table 1). The diagnosis had been established using the criteria defined by the American Thoracic Society. Respiratory symptoms were well controlled by administration of theophylline or inhaled β agonists which were part of their therapeutic regimen. Treatment with drugs affecting bronchial responsiveness such as steroids or inhaled cromolyn had been suspended during the month before the beginning of the study if the patient had been taking them previously. Eight had a positive skin test reaction to aeroallergens but were not exposed to the relevant allergens during the study. Pregnant patients or nursing mothers were excluded as were patients with clinically significant cardiac, renal, hepatic or metabolic disease. All subjects had proven airway hyperresponsiveness – that is, a 20% decrease in forced expiratory volume in one second (FEV₁) with ≤1500 μg methacholine (the method of methacholine challenge is described below). Basal FEV₁ values were above 70% of the predicted value for all subjects. Patients gave written informed consent prior to participation in the study.

DRUGS AND TRIAL DESIGN

The test medications were Theo-Dur (200 mg, twice daily sustained release theophylline tablets; Recordati Spa, Milan, Italy) and Diffumal-24 (200 mg, once daily sustained release theophylline tablets; Malesci Spa, Florence, Italy).

Diffumal-24 is an ultrastaged release theophylline formulation that produces peak theophylline concentration 10 hours after the oral administration of 600 mg (personal unpublished results). All the tablets could be broken in half. A matching placebo was also used to allow the study to be blind.

The study began with a theophylline dosage titration period. While taking their prettrial slow release theophylline twice a day each patient had his/her dosage adjusted, if necessary, to produce morning theophylline concentrations of ≥8 mg/l. This theophylline dose was then administered as a single dose of Diffumal-24 at 08.00 hours or divided into two doses of Theo-Dur at 08.00 and 20.00 hours.

The study was of a double blind, crossover, placebo controlled design. Patients were assigned to treatments according to a 3 × 3 latin square design and received orally for seven days, in three separate periods, either placebo, once daily sustained release theophylline, or the same dosage of twice daily sustained release theophylline. The placebo and both once daily and twice daily theophylline formulations were contained in identical wafers. The procedure was as follows: (1) two wafers containing placebo in the morning and two in the evening; (2) two wafers containing Theo-Dur at 08.00 hours and two at 20.00 hours; (3) two wafers containing placebo at 08.00 hours and two wafers containing Diffumal-24 at 20.00 hours.

The three treatment periods were separated by a washout period of at least three days. Inhaled β agonists were continued throughout the trial and patients were asked to keep the daily dosage of these medications constant until the seventh day of each treatment period at which time they were withheld for 12 hours before performing spirometric tests and the methacholine challenge. Drugs known to affect theophylline metabolism were withdrawn during the study regimen. Treatment with drugs as specified). On the seventh day of each treatment period the patients underwent spirometric tests and bronchial challenge with methacholine at 08.00, 14.00, and 20.00 hours. At these times blood samples were taken for theophylline analysis.

SPIROMETRIC TESTING AND BRONCHIAL CHALLENGE

Forced expiratory volume in one second (FEV₁) was measured using a water sealed spirometer (Biomedin, Padua, Italy) and the bronchial challenge with methacholine was carried out using an ampoule dosimeter device (Mefar, Brescia, Italy). The dosimeter was triggered by an inspiration activated solenoid valve which remained open for one second to allow the generation of an aerosol with pressured air of 1.5 kg/cm². Two solutions of methacholine (Sigma Chemie, 0.1% and 1.0%, respectively) in a phosphate buffer were prepared daily. After an initial inhalation of phosphate buffer only, methacholine was inhaled by
Dosage frequency of sustained release theophylline in asthma

971

FEV1 (PD20). We calculated this datum by the bronchial challenge were expressed by the ured after the bu more than 20% compared with the value meas-
ted after the buffer challenge. The results of the bronchial challenge were expressed by the dosage of methacholine causing a 20% fall of FEV1 (PD20). We calculated this datum by interpolating in the semilogarithmic dose-re-

time was performed. A Duncan test for multiple to Di-

ff

effects, separate analysis by treatment and by Di-

ff

time was statistically signi®cant (p<0.001). periods.

The mean theophylline concentrations are and no di-

ff

to incorrect estimates of treatment and time measured over the 12 hour period were similar

ff

di-

ff

is, the relative e

ff

effects of treatments varied mark-

ff

ded at different sample times – thus leading to incorrect estimates of treatment and time

effects, separate analysis by treatment and by time was performed. A Duncan test for multiple comparisons was used to assess the grouping of treatments and times when the corresponding ANOVA F test was significant at the specified alpha level.

STATISTICAL ANALYSIS
The data are expressed as mean (SE) values. Analysis of variance (ANOVA) for repeated measures was first performed to assess the relevance of various factors (treatment, time of sample collection, and treatment by time interaction) in explaining the observed changes in FEV1, PD20, and theophylline serum levels. PD20 values were log transformed (natural logarithm, lnPD20) before the analysis. If the interaction term was statistically significant – that is, the relative effects of treatments varied markedly at different sample times – thus leading to incorrect estimates of treatment and time effects, separate analysis by treatment and by time was performed. A Duncan test for multiple comparisons was used to assess the grouping of treatments and times when the corresponding ANOVA F test was significant at the specified alpha level.

Results

SERUM THEOPHYLLINE CONCENTRATIONS AND β
AGONIST USE
The mean daily theophylline dose during the trial period was 708.3 mg (range 600–900 mg). The mean theophylline concentrations are shown in fig 1. The interaction term treatment by time was statistically significant (p<0.001).

Serum theophylline concentrations were undeterminable during the placebo treatment period in all the patients. Diffumal-24 produced a significantly higher serum theophylline concentration than Theo-Dur at 08.00 hours (16.6 (1.1) versus 10.1 (0.6) mg/l, p<0.001). However, at 20.00 hours serum theophylline levels after Theo-Dur (10.8 (1.0) mg/l) were higher than those seen after Diffumal-24 (8.3 (0.7) mg/l, p<0.01). No difference in theophylline concentration between the two drugs was found at 14.00 hours (Theo-Dur, 12.3 (1.0) mg/l; Diffumal-24, 11.2 (0.9) mg/l). Within-drug comparison revealed that during the Diffumal-24 treatment period the mean serum theophylline concentrations at 08.00, 14.00, and 20.00 hours were significantly different from one another (p<0.01). During Theo-Dur dosing there was no difference between the mean concentrations of theophylline measured at 08.00 hours and 20.00 hours, but at 14.00 hours the mean concentration was significantly higher.

The relative bioavailabilities of theophylline measured over the 12 hour period were similar with both therapeutic regimens, the Theo-Dur to Diffumal-24 ratio of the area under the concentration-time curve being 0.96. At 08.00 hours one patient had a serum theophylline concentration below 8 mg/l (7.8 mg/l) after treatment with Theo-Dur, and one patient had a serum theophylline concentration above 20 mg/l (23 mg/l) after treatment with Diffumal-24. No patient complained of clinically significant adverse effects following administration of theophylline.

The mean daily dosage of inhaled β agonist was one puff three times daily. The patients were asked to keep the daily dosage constant and no difference in the frequency of β agonist use was found during the three treatment periods.
BRONCHIAL CHALLENGE WITH METHACHOLINE
The changes in methacholine hyperresponsiveness expressed as lnPD$_{20}$ are shown in fig 2. In table 2 the differences at each time between treatments, with 95% confidence interval (CI), are reported. The interaction term treatment by time was statistically significant (p<0.05). During placebo administration the mean values of lnPD$_{20}$ were 4.70 (0.28) at 08.00 hours, 5.01 (0.34) at 14.00 hours and 5.35 (0.32) at 20.00 hours. The lnPD$_{20}$ measured at 08.00 hours was significantly lower than that obtained at 20.00 hours (p<0.01) whereas no difference was found between the values recorded at any other time.

With Theo-Dur the lnPD$_{20}$ was increased, though not significantly (5.18 (0.31) at 08.00 hours, 5.81 (0.37) at 14.00 hours, 5.6 (0.36) at 20.00 hours) relative to placebo at each testing time. During Diffumal-24 treatment the lnPD$_{20}$ values were 5.73 (0.36), 5.75 (0.47), 5.29 (0.44) at 08.00, 14.00, and 20.00 hours, respectively. At 08.00 hours the differences between lnPD$_{20}$ values recorded after Diffumal-24 and placebo was statistically significant (p<0.01, p<0.05, respectively; table 2). No difference between treatments was found at 14.00 hours and 20.00 hours. When the patients with theophylline serum levels below 8 mg/l were withdrawn from the analysis the differences between the effect of Diffumal-24 and Theo-Dur on methacholine induced bronchoconstriction at 08.00 hours was still significant.

Diffumal-24 stabilised the bronchial response to methacholine so that there was no significant difference between the mean values of lnPD$_{20}$ at 08.00, 14.00, and 20.00 hours. However, during Theo-Dur treatment the mean values of lnPD$_{20}$ at 08.00 hours were significantly lower than at 14.00 hours (p<0.05).

The mean FEV$_1$ values at each measurement time after placebo, Theo-Dur, and Diffumal-24 are shown in fig 3 and in table 3 the differences at each time between treatments with 95% CI are reported. The interaction term treatment by time was statistically significant (p<0.03).

After placebo the mean (SE) FEV$_1$ values were 2.8 (0.2), 3.0 (0.3), 2.9 (0.3) l at 08.00, 14.00, and 20.00 hours, respectively. There was no statistically significant difference in FEV$_1$ between any time points while on placebo. The once daily theophylline formulation (Diffumal-24) resulted in significantly higher FEV$_1$ values at 08.00 hours (3.2 (0.3) l) than at 20.00 hours (2.9 (0.2) l; p<0.02) which, in turn, were significantly lower than at 14.00 hours (3.1 (0.3) l;
Dosage frequency of sustained release theophylline in asthma

During the Theo-Dur treatment period there were no significant differences between FEV1 at 08.00 hours (3.0 (0.2) l), 14.00 hours (3.1 (0.2) l), and 20.00 hours (3.0 (0.2) l). The once a day formulation of theophylline produced significantly greater bronchodilation than placebo at 08.00 hours (p<0.01) whereas the twice a day formulation did not. No significant difference was found in FEV1 between treatments at 14.00 hours and 20.00 hours.

**Discussion**

During placebo administration the lowest mean values of PD20 were found at 08.00 hours with a progressive increase in the parameter at 14.00 and 20.00 hours, consistent with previous reports of diurnal variation in airway responsiveness.16 Despite the substantial morning fall in PD20 there was no significant daytime variation in FEV1. These data support the hypothesis that the increase in bronchial responsiveness is not dependent on, or need not result in, airflow obstruction.17

The administration of the once daily theophylline formulation at 20.00 hours produced a decrease in the morning sensitivity to methacholine that was significantly greater than that seen after the twice daily regimen. The better protective effect of Diffumal-24 compared with Theo-Dur may be due to the higher serum theophylline concentrations obtained at 08.00 hours and suggests a dose-related effect of theophylline on bronchial hyperresponsiveness.16-20 Another explanation for the better protective effect against methacholine seen with Diffumal-24 might be the higher mean FEV1 values registered at 08.00 hours after administration of the once daily theophylline (see below). However, the difference between FEV1 value at 08.00 hours after Theo-Dur and Diffumal-24 was slight and not statistically significant so an alternative hypothesis, such as an effect of theophylline on bronchial responsiveness not dependent on its bronchodilating activity, cannot be excluded.

The morning advantage of this particular once a day theophylline formulation – that is, the greater effect on airways at 08.00 hours in comparison with the conventional twice daily theophylline treatment – was not associated with a deterioration in the state of the airway during the day; the protective activity against methacholine of Diffumal-24 and Theo-Dur at 14.00 hours and 20.00 hours was not significantly different even if higher theophylline serum levels were attained at 20.00 hours with the twice a day formulation. Furthermore, even though the fluctuation in serum theophylline concentration was considerably greater during treatment with the once a day theophylline formulation, the variability over 24 hours in PD20 was far less, indicating a greater stability of bronchial hyperresponsiveness with the evening administration of the once daily theophylline formulation. These findings indicate that, when low grade airway reactivity is present (as in the evening), it is unnecessary to attain high theophylline serum concentrations. On the contrary, it is of critical importance to produce the maximum serum theophylline concentrations in the early morning which is the time when bronchial hyperresponsiveness is highest.

Our study therefore adds a further piece of evidence in favour of the concept that optimal control of asthma requires that maximum concentrations of theophylline are achieved at the time of the patient’s greatest need for airway protection11 rather than minimisation of fluctuation in serum levels of the drug.21,22

After evening administration of the once a day formulation there was a significant increase in FEV1 values in the morning compared with placebo which did not occur after Theo-Dur. However, no difference between the effect of the two theophylline products was found at 14.00 and 20.00 hours. These findings confirm previous studies showing that once daily theophylline therapy is as effective or more so than twice daily therapy for controlling asthma in patients with severe10,12 or moderately severe10,28 airflow limitation. They also show that the drug has a similar benefit in patients with mild bronchial obstruction.

After treatment with the once a day theophylline formulation only one subject had theophylline serum levels above 20 mg/l in the morning. We cannot exclude that serum concentrations above the therapeutic range might have occurred in other patients during the night, even though none complained of clinically relevant adverse effects. This point must be carefully considered when the total dose of theophylline is administered in the evening.

The design of our study did not enable us to check for carry over effects of treatment. However, carry over effects are unlikely since a washout period of at least three days (which in many patients lasted for 4–6 days) seems adequate to eliminate theophylline completely in patients without cardiac or hepatic disease.

In conclusion, our results have shown that a once a day theophylline formulation taken in the evening compared with a twice a day formulation results in a higher serum theophylline concentration in the morning when maximum airflow narrowing and hyperresponsiveness occur. This improves bronchial obstruction and significantly reduces sensitivity to methacholine in the morning without a deterioration in the state of the airways during the daytime. Although it is tempting to speculate that the clinical use of a theophylline ultrascarnulted release formulation is justified by its efficacy in decreasing bronchial hyperresponsiveness as well as its established bronchodilator effectiveness,1 long term studies are necessary to support this hypothesis definitively. Moreover, further investigations are needed to clarify whether the results obtained in our patients might be applied to subjects with more severe disease and/or with more severe bronchial hyperresponsiveness.

974  

Effect of once daily and twice daily sustained release theophylline formulations on daytime variation of bronchial hyperresponsiveness in asthmatic patients.

M Ferrari, M Olivieri, G Lampronti, L Bonazza, C Biasin, P Nacci, G Talamini and V Lo Cascio

Thorax 1997 52: 969-974
doi: 10.1136/thx.52.11.969

Updated information and services can be found at:
http://thorax.bmj.com/content/52/11/969

Email alerting service

These include:

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections

Articles on similar topics can be found in the following collections

Drugs: respiratory system (526)
Asthma (1782)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/